Qiagen, Lilly Ink Third Companion Test Agreement for Undisclosed Compound | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen and Lilly inked their third companion diagnostic deal this week.

The companies did not disclose the drug or the molecular diagnostic target that the test will gauge.

Qiagen highlighted that the latest deal "builds on a master collaboration agreement for development of tailored therapies in cancer and other therapeutic areas signed earlier this year."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.